Size-dependent extravasation and interstitial localization of polyethyleneglycol liposomes in solid tumor-bearing mice

Ishida, Osamu; Maruyama, Kazuo; Sasaki, Katsunori; Iwatsuru, Motoharu

doi:10.1016/s0378-5173(99)00256-2

Cited by 286 publications

(165 citation statements)

References 13 publications

Supporting

Mentioning

157

Contrasting

Unclassified

Order By: Relevance

“…In addition, the combination of transferrin-based active targeting with the passive targeting resulting from the enhanced permeability and retention effect [15] provides a tumor-selective targeting to this delivery system [16]. Among the various formulations investigated, multilamellar vesicles conjugated to 12 mg Tf and entrapping 2 mg of -T3 were found to give the highest efficacy against A431 cell viability.…”

Section: Discussionmentioning

confidence: 99%

Tumor regression after intravenous administration of targeted vesicles entrapping the vitamin E α-tocotrienol

Karim

Somani

Robaian

et al. 2017

Journal of Controlled Release

View full text Add to dashboard Cite

The therapeutic potential of tocotrienol, a member of the vitamin E family of compounds with potent in vitro anti-cancer properties, is limited by its inability to specifically reach tumors following intravenous administration. The purpose of this study is to determine whether a novel tumor-targeted vesicular formulation of tocotrienol would suppress the growth of A431 epidermoid carcinoma and B16-F10 melanoma in vitro and in vivo.In this work, we demonstrated that novel transferrin-bearing multilamellar vesicles entrapping -T3 resulted in a dramatically improved (by at least 52-fold) therapeutic efficacy in vitro on A431 cell line, compared to the free drug. In addition, the intravenous administration of tocotrienol entrapped in transferrin-bearing vesicles resulted in tumor suppression for 30% of A431 and 60% of B16-F10 tumors, without visible toxicity. Mouse survival was enhanced by more than 13 days compared to controls administered with the drug solution only. This tumor-targeted, tocotrienol-based nanomedicine therefore significantly improved the therapeutic response in cancer treatment. KEYWORDSTocotrienol; transferrin; tumor targeting; delivery system; cancer therapy 2 1. Introduction Tocotrienol, a member of the vitamin E family of compounds, is currently receiving increased attention because of its promising anti-tumor activity [1,2]. It has been reported to exert its anti-cancer effects through various mechanisms, such as activation of p53, modulation of Bax/Bcl-2 ratio, decrease of oxidative stress and induction of apoptosis [1][2][3][4]. It can also inhibit angiogenesis by downregulating the expression of the vascular endothelial growth factor (VEGF) receptor and blocking intracellular VEGF signaling. In addition, it is able to potentiate apoptosis through inhibition of DNA polymerase and telomerase and of NF-B activation pathway [1][2][3][4]. This wide range of anti-cancer effects therefore makes tocotrienol a very promising therapeutic molecule. However, its efficacy against cancer cells in vivo is hindered by its inability to specifically reach cancer cells at a therapeutic concentration, without affecting normal cells. Given its anti-proliferative properties, it is of the utmost importance to find a strategy to deliver this therapeutic drug specifically to its site of action. On the basis that iron is essential for tumor cell growth and can be effectively carried to tumors by using transferrin receptors overexpressed on cancer cells [5,6], we recently demonstrated that the conjugation of transferrin (Tf) to vesicles entrapping tocotrienol-rich fraction (TRF) extracted from palm oil could lead to tumor regression, and even tumor suppression, on both the tested cancer cell lines, following intravenous injection to a murine model [7][8][9]. It resulted in complete tumor eradication for 50% of B16-F10 tumors and 20% of A431 tumors [7]. The treatments were well tolerated by the animals, without weight loss or apparent signs of toxicity. These previous studies, however, used TRF but did not ev...

show abstract

Section: Discussionmentioning

confidence: 99%

Tumor regression after intravenous administration of targeted vesicles entrapping the vitamin E α-tocotrienol

Karim

Somani

Robaian

et al. 2017

Journal of Controlled Release

View full text Add to dashboard Cite

show abstract

“…[125][126][127] It should be mentioned that nanoparticles within the size range of 60-400 nm are effective for this type of targeting. 128,129 These are three in vivo studies based on the permeation and retention effect. Bhardwaj et al formulated PLGApaclitaxel nanoparticles stabilized with DMAB and administered orally to female Sprague Dawley rats.…”

Section: Passive Targetingmentioning

confidence: 99%

Polylactide-co-glycolide nanoparticles for controlled delivery of anticancer agents

Dinarvand¹,

Sepehri²,

Manoochehri³

et al. 2011

IJN

390

265

View full text Add to dashboard Cite

The effectiveness of anticancer agents may be hindered by low solubility in water, poor permeability, and high efflux from cells. Nanomaterials have been used to enable drug delivery with lower toxicity to healthy cells and enhanced drug delivery to tumor cells. Different nanoparticles have been developed using different polymers with or without surface modification to target tumor cells both passively and/or actively. Polylactide-co-glycolide (PLGA), a biodegradable polyester approved for human use, has been used extensively. Here we report on recent developments concerning PLGA nanoparticles prepared for cancer treatment. We review the methods used for the preparation and characterization of PLGA nanoparticles and their applications in the delivery of a number of active agents. Increasing experience in the field of preparation, characterization, and in vivo application of PLGA nanoparticles has provided the necessary momentum for promising future use of these agents in cancer treatment, with higher efficacy and fewer side effects.

show abstract

“…greater than 50% fatalities with Ն8 nmol lipid/g DNA formulations). Since (1) liposomes with an average diameter of 100-200 nm have been shown to have the greatest tumor accumulation; 30 (2) the endocytosis pathway can accommodate only particles with a maximal diameter of 100-150 nm; 31,32 and (3) no fatalities were observed in cohorts receiving the 5 nmol lipid/g DNA formulations, we chose to use the 5 nmol lipid/g DNA formulations for the remainder of our studies. Notably, the highest luciferase-mediated light emission was detected in tissues 24 h post administration, but the activity then decreased rapidly and reduced to 50% of maximum by 48 h. Thus, for subsequent in vivo studies we chose to measure tissue transfection activity 24 h post administration.…”

Section: Optimization Of Cationic Liposome/dna Complex For Transgene mentioning

confidence: 99%

Folate-targeted, cationic liposome-mediated gene transfer into disseminated peritoneal tumors

Reddy

Abburi

Hofland³

et al. 2002

Gene Ther

161

View full text Add to dashboard Cite

Size-dependent extravasation and interstitial localization of polyethyleneglycol liposomes in solid tumor-bearing mice

Cited by 286 publications

References 13 publications

Tumor regression after intravenous administration of targeted vesicles entrapping the vitamin E α-tocotrienol

Tumor regression after intravenous administration of targeted vesicles entrapping the vitamin E α-tocotrienol

Polylactide-co-glycolide nanoparticles for controlled delivery of anticancer agents

Folate-targeted, cationic liposome-mediated gene transfer into disseminated peritoneal tumors

Contact Info

Product

Resources

About